Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label pharmacokinetics and safety study of aripiprazole IM depot (OPC-14597 IMD) deltoid injections in schizophrenia
jRCT2080222584Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Plasma aripiprazole concentration steady-state after repeated deltoid IM depot injections and Safety and tolerability of repeated aripiprazole IM depot 400 mg deltoid injections. Started Aug 2014; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080222584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222584.